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Cytokine-activated receptors initiate intracellu-
lar signaling by recruiting protein kinases that
phosphorylate the receptors on tyrosine resi-
dues, thus enabling docking of SH2 domain-
bearing activating factors. Here we report that
in response to type 1 interferon (IFNa), IFNa
receptors recruit cytoplasmic CREB-binding
protein (CBP). By binding to IFNaR2 within the
region where two adjacent proline boxes bear
phospho-Ser364 and phospho-Ser384, CBP
acetylates IFNaR2 on Lys399, which in turn
serves as the docking site for interferon regu-
latory factor 9 (IRF9). IRF9 interacts with the
acetyl-Lys399 motif by means of its IRF ho-
mology2 (IH2) domain, leading to formation of
the ISGF3 complex that includes IRF9, STAT1,
and STAT2. All three components are acety-
lated by CBP. Remarkably, acetylation within
the DNA-binding domain (DBD) of both IRF9
and STAT2 is critical for the ISGF3 complex
activation and its associated antiviral gene reg-
ulation. These results have significant implica-
tions concerning the central role of acetylation
in cytokine receptor signal transduction.
INTRODUCTION
IFNaR1 and IFNaR2 belong to class II transmembrane
cytokine receptors that are shared by all type I IFN family
members. Despite their similarity, neither one can function
independently during signaling for IFNa. By binding to
IFNaR1 and IFNaR2, IFNa triggers their oligomerization
and receptor-associated Janus tyrosine kinase (JAK)
activation, leading to receptor tyrosine phosphorylation.
Among the cytoplasmic molecules responding to IFNa
for activation, signal transducer and activator of transcrip-
tion (STAT) proteins are the most prominent SH2 domainbearing transcription factors recruited by IFNa receptors
for transcriptional regulation. Although IFNa can activate
all seven STAT members, STAT1 and STAT2 activation
have been most closely linked to IFNa’s antiviral activity.
While STAT2 can be recruited by both IFNaR2 and
IFNaR1, STAT1 activation by IFNa mainly depends on
the presence of STAT2 in the cell (Leung et al., 1995).
STAT2 binds to IFNaR2 much stronger than it binds
to IFNaR1 (Saleh et al., 2002), suggesting a prominent
role of IFNaR2 in STAT recruitment and activation. How-
ever, STAT2 recruitment by IFNaR2 can be both IFNaR2
tyrosine phosphorylation-dependent and -independent
(Nguyen et al., 2002; Wagner et al., 2002). Moreover,
when STAT2 contains a bB Arg / Gln mutation in the
SH2 domain, it can still be recruited by the IFNa receptor;
and STAT1 and STAT2 still can form heterodimers inde-
pendent of their phosphorylation status (Stancato et al.,
1996; Li et al., 1997). This indicates that additional post-
translational modification events may be involved in the
IFNa receptor-STAT pathway activation.
STAT2 is notably distinct from the rest of STAT family
members as its b-barrel DNA-binding domain (DBD) is
essentially not involved in DNA binding. STAT2 acts as
an adaptor to recruit STAT1 either to IFNaR2 for activation
or to IRF9 to form the interferon-stimulated gene factor
3 (ISGF3) complex. The IFNa activated ISGF3 complex
translocates to the nucleus, where it binds to the inter-
feron-stimulated response element (ISRE) present in the
promoters of many antiviral genes. Within the ISGF3 com-
plex, IRF9 and STAT1 cooperatively contact the ISRE
element at neighboring bases. The N-terminal domain
(1–120 residues) of IRF9, a highly conserved helix-turn-
helix structure among all IRF family members, is responsi-
ble for DNA binding. The C-terminal domain of IRF9, is
also largely conserved among many IRF family members
(except IRF1 and IRF2) and is homologous to the MAD ho-
mology2 (MH2) domain of SMAD proteins (Qin et al., 2003;
Takahasi et al., 2003). The MH2 domain of SMAD may play
an important role in TGFb receptor association and SMAD
dimerization (Wu et al., 2001). It is worthwhile to note that
the MH2 domain of SMAD3 is acetylated, suggesting
a role of this domain in acetylation-relevant signalCell 131, 93–105, October 5, 2007 ª2007 Elsevier Inc. 93
Figure 1. IFNaR2 Recruits CBP upon IFNa Treatment
(A) Cytoplasmic and nuclear fractions, prepared from HeLa cells treated with or without IFNa for indicated times, were analyzed in Western blot with
different antibodies as indicated.
(B) Confocal images of HeLa cells treated with or without IFNa stained with anti-CBP or 4,6-diamidino-2-phenylindole (DAPI) as indicated.
(C) The endogenous CBP or IRF9 was precipitated with IFNaR2 in HeLa cells treated with or without IFNa for 30 min. Immunoprecipitation (IP) was
done with anti-IFNaR2.
(D) CBP immunoprecipitates recovered both HA-CBP and HA-IFNaR2 in 293Tcells when HA-CBP and HA-IFNaR2 were cotransfected.
(E) A schematic illustration of the full length (K265-R515) and various truncation mutations of IFNaR2 cytoplasmic region (IFNaR2C) tagged with
6xMyc.
(F) IFNaR2 ‘‘336-391’’ bears the CBP binding site. In 293T cells, empty vector (EV) and the above constructed Myc-IFNaR2C were cotransfected with
HA-CBP. Anti-HA precipitates prepared from these transfectants were blotted with anti-Myc or anti-HA.
(G) Phospho-Ser364 and phospho-Ser384 of IFNaR2 cooperatively provide CBP for binding. Myc-IFNaR2C wild-type (WT) and serine mutants as
indicated were cotransfected with HA-CBP in 293T cells. Anti-HA precipitates were blotted with anti-Myc or anti-HA.transduction (Inoue et al., 2006). For IRF members, serine
phosphorylation within the C-terminal regulatory domain
is related to their activation by viruses or by Toll-like recep-
tor ligation. In addition to C-terminal serine phosphoryla-
tion, both SMAD and IRF members undergo CBP/p300-
mediated acetylation modification within their N-terminal
DBD (Masumi et al., 2003; Caillaud et al., 2002). Although
CBP/p300 and cofactors exclusively enhance transcrip-
tional activity of IRF or SMAD, the functional significance
of acetylation within the DBD for transcriptional activity
remains unclear.
The molecular mechanism of IRF9 activation leads to
ISGF3 complex formation, and its subsequent DNA bind-
ing remains a critical missing link in understanding IFNa
signaling. Recently, we showed that STAT3 activation by
cytokines including IFNa required CBP/p300-mediated
acetylation (Yuan et al., 2005). The cytoplasm is a de facto
arena for STAT to undergo dynamic posttranslational
modifications, including both phosphorylation and acet-
ylation, suggesting CBP/p300 may function as a cyto-
plasmic acetyltransferase in cells. In view of the direct in-
teraction between CBP/p300 and STAT2, which is
IFNa stimulation dependent and required for subsequent
ISGF3 antiviral activity (Bhattacharya et al., 1996), it is
possible that CBP/p300 acetyltransferase activity is under94 Cell 131, 93–105, October 5, 2007 ª2007 Elsevier Inc.the immediate regulation of the IFNa receptor. In this
report, we demonstrate that in IFNa-treated cells IFNaR2
recruits CBP to initiate an acetylation cascade in cyto-
plasm. Although CBP exists mainly in nuclei of quiescent
cells, IFNa treatment accelerates its cytoplasmic accumu-
lation. A detailed protein-interaction analysis reveals that
CBP-acetylated IFNaR2 and IRF9 undergo modular inter-
action, leading to ISGF3 activation. Thus, acetylation
plays a critical role in activation of cytokine receptors
and their downstream signaling molecules.
RESULTS
IFNaR2 Phosphorylation on Ser364 and Ser384
Coordinately Recruits Cytoplasmic CBP
To investigate IFNa-stimulated acetylation of the ISGF3
components, we examined the subcellular localization of
various HAT proteins before and after IFNa treatment of
HeLa cells. Both p300 and CBP were detectable in the
cytoplasmic fraction prepared from HeLa cells, albeit at
relatively low levels. Upon IFNa treatment, however, the
steady-state cytoplasmic CBP level was increased, ac-
companied by a gradual reduction of nuclear CBP levels
(Figure 1A). This finding suggested that CBP may normally
shuttle between the cytoplasm and the nucleus and that
IFNa treatment can promote this process. Meanwhile, we
observed that IRF9 and STAT2 nuclear translocation upon
IFNa treatment (Figure 1A) is in agreement with the previ-
ous observation (Levy et al., 1989). IFNa-mediated CBP
nuclear export in HeLa cells as well as other type of cells
was further documented by confocal laser microscopy
analysis (Figures 1B and S1A). These findings prompted
us to explore whether IFNa receptors could recruit CBP.
In HeLa cells or mouse fibroblasts, CBP was associated
with IFNaR2, and this association was enhanced upon
IFNa treatment (Figures 1C and S1B). Similarly, IRF9 and
IFNaR2 also coprecipitated (Figure 1C). It is worthwhile
to note that the CBP and IFNaR2 coprecipitation was
only detected in the cytoplasmic fraction, suggesting
that IFNaR2 recruits CBP from the cytoplasm rather than
from the nucleus (Figure S1B). The interaction between
CBP and IFNaR2 detected in HeLa cells was confirmed
by recovering IFNaR2 from anti-CBP precipitates
prepared from 293T cells transiently transfected with
HA-tagged IFNaR2 and HA-tagged CBP (Figure 1D).
When IFNaR1 was cotransfected with CBP, IFNaR1 and
CBP association was also detected (data not shown). In
addition, both IFNaR2 and IFNaR1 were able to recruit
p300 (Figures S1C and S1D). Thus, the two subunits of
the IFNa receptor not only recruit JAK and STAT, as has
been previously reported, but they also recruit CBP/
p300 and IRF9.
The cytoplasmic region of human IFNaR2 is serine rich
and bears six putative proline boxes. To establish the
CBP- binding domain, a series of cDNAs encoding
a Myc-tagged IFNaR2 cytoplasmic region with various
truncation were constructed (Figure 1E). In 293T cells,
the Myc-IFNaR2 C-terminal truncation mutants were
cotransfected with HA-CBP for an association analysis.
Slightly enhanced CBP binding was detected when com-
paring the C-terminally truncated deletion construct
(265–473) with the full-length C-terminal region (265–515)
(Figure 1F), indicating that the C terminus of IFNaR2 bears
an inhibitory regulation domain. IFNaR2 mutants inter-
acted with CBP when the C-terminal end was truncated
up to Ser392. Further truncation up to Gly335 largely
disrupted the IFNaR2:CBP interaction (Figure 1F). In
accord with this, while deletion of the membrane proximal
region between Lys265 and Gly335 showed no ap-
parent effect on IFNaR2:CBP interaction, further deletion
up to Leu391 abrogated the IFNaR2:CBP interaction
(Figure 1F).
Among the phosphoserines identified by mass spec-
trometry (Table S1), Ser364 and Ser384 reside within
the two adjacent proline box 2 and proline box 3
(P362xxxxxPxxP, P378xxPxxxP) of the region between
Gly335 and Ser391. To determine the importance of serine
phosphorylation on CBP interaction, we prepared serine
mutated IFNaR2. While IFNaR2 mutants with S322A/
S324A, S400A, or S412A/S413A substitutions retained
their ability in recruiting CBP, either S364A or S384A of
IFNaR2, but not with S364D or S384D substitution, largely
abolished CBP recruitment (Figure 1G). Together, theseresults suggest that while the region from Gly335 to
Ser392 is responsible for CBP binding, phosphorylation
of Ser364 and Ser384 sites coordinately stabilize this
binding.
IFNaR2 Acetylation by CBP on Lys399 Provides
the Docking Site for IRF9
To gain insight into the role of cytoplasmic CBP recruit-
ment by IFNa receptors, we examined IFNaR2 acetyla-
tion. In HeLa cells, IFNaR2 acetylation was induced by
IFNa treatment and downregulation of CBP in HeLa cells
with CBP-specific siRNA-abolished IFNaR2 acetylation
in response to IFNa treatment (Figure 2A), suggesting
that CBP is responsible for IFNaR2 acetylation in HeLa
cells. Although p300 and IFNaR2 interaction was detected
(Figure S1C), CBP was much more effective than p300 or
other acetyltransferase factors at catalyzing IFNaR2 acet-
ylation (Figure 2B, upper panel). CBP-dependent IFNaR2
acetylation could be enhanced by treating the transfec-
tants with trichostatin A (TSA), a synthetic inhibitor of his-
tone deacetylase (HDAC) or abolished by cotransfecting
with HDAC6 (Figure 2B, bottom panel), suggesting CBP-
mediated IFNaR2 acetylation is a reversible process.
The IFNaR2 cytoplasmic region carries a number of
species-conserved lysine sites. To identify the acetylated
lysine site(s), IFNaR2 mutants were constructed, in which
each of these lysine residues was changed to arginine
via site-directed mutagenesis. IFNaR2-KR mutants were
transfected along with CBP in 293T cells and assessed
for their acetylation pattern. IFNaR2 acetylation intensity
was markedly reduced with the Lys399/ Arg substitu-
tion (Figure 2C), suggesting that Lys399 may be the major
acetylation site of the IFNaR2 cytoplasmic region. To
confirm this finding, IFNaR2 proteins purified from IFNa-
treated 293T transfectants were analyzed with MALDI-
TOF mass spectrometry. The specific peptide sequences
of IFNaR2 were assigned to the mass values shown in
Figure 2D by matching the measured masses with calcu-
lated mass values. Mass spectrometry analysis not only
confirmed Lys399 as the unique acetylation site but also
identified seven phosphorylated serine residues including
Ser400 (Figure 2D and Table S1) as described in the above
section. Notably, the peptides bearing acetyl-Lys399-
phospho-Ser400 (Figure 2D), acetyl-Lys399 alone, and
phospho-Ser400 alone (Table S1) were simultaneously re-
covered in the mass spectrometry analysis, indicating that
Lys399 acetylation and Ser400 phosphorylation can hap-
pen either simultaneously or independently. Intriguingly,
the ‘‘RRKSPL’’ motif of IFNaR2 is homologous to Lys9
and Lys27 of the histone H3 protein (Figure 2E). In histone
H3, the ‘‘RKS’’ motifs are involved in protein interactions
by following a ‘‘meth/phos switch’’ model (Fischle et al.,
2005; Hirota et al., 2005). This raises the possibility that
the dual-mark combination of acetyl-Lys399phospho-
Ser400 serves as a better protein-protein interaction
module for signal transduction.
To explore the consequence of IFNaR2 acetylation
in signal transduction, we analyzed STAT and IRF9Cell 131, 93–105, October 5, 2007 ª2007 Elsevier Inc. 95
Figure 2. IFNaR2 Is Acetylated on Lys399 by CBP
(A) Antiacetylated lysine blotting analysis showed that IFNaR2 was acetylated in HeLa cells treated with IFNa. IFNa-induced IFNaR2 acetylation was
abolished in HeLa cells transfected with CBP specific siRNA.
(B) IFNaR2 acetylation was analyzed by cotransfecting IFNaR2 with different HAT factors as indicated in 293T cells (upper panel). IFNaR2 acetylation
was estimated in 293T cells transfected with IFNaR2-HA alone; IFNaR2-HA and CBP; or IFNaR2-HA, CBP, and HDAC6 together followed by treat-
ment with or without TSA (1 mM) for 6 hr (bottom panel).
(C) K399R substitution largely abolished IFNaR2 acetylation by CBP in 293T transfectants. Anti-HA (IFNaR2) precipitates from these transfectants
were probed with antiacetylated lysine or anti-HA as indicated.
(D) MS/MS spectrum of the peptide demonstrating Lys399 acetylation and Ser400 phosphorylation of IFNaR2 protein prepared from 293T transfec-
tants treated with IFNa. Singly and doubly charged b and y ions are shown above and below the peptide sequence.
(E) Comparing IFNaR2 acetylated-phosphorylated sequence with the ‘‘K9S10,’’ ‘‘K27S28,’’ and ‘‘K56S57’’ motifs of histone-H3 and the ‘‘K370S371’’
motif of p53.recruitment by IFNaR2, since IFNaR2 could recruit not
only STAT2 but also IRF9 (Figures 3A and 1C). To identify
the IRF9 docking site in IFNaR2, truncation mutations of
IFNaR2 cytoplasmic domain were tested for IRF9 binding.
C-terminally truncated IFNaR2 (265–408) interacted with
IRF9 with no apparent binding defect (Figure 3B, left
panel). After further truncation up to Ser392 (265–392),
the interaction with IRF9 was disrupted (Figure 3B, left
panel) without apparently affecting its interaction with
STAT2 (Figure 3B, right panel). Hence, the 16-residue
fragment from Ser392 to Glu408 of the IFNaR2 cytoplas-
mic domain, which bears Lys399 and Ser400, should be
specifically responsible for IRF9 binding.
To estimate Lys399/Ser400 modification in IRF9 recruit-
ment, we constructed IFNaR2 with Lys399 and/or Ser400
mutations. IFNaR2-K399R reduced its interaction with
IRF9 (Figure 3C). Interestingly, a slightly enhanced interac-
tion between IFNaR2-S400A mutant and IRF9 was repeat-
edly observed (Figure 3C). When both K399R and S400A96 Cell 131, 93–105, October 5, 2007 ª2007 Elsevier Inc.were introduced, however, the activity of IFNaR2 in IRF9
interaction was severely affected (Figure 3C). Mass spec-
trometry showed that IFNaR2 was phosphorylated on
Ser322, Ser324, Ser412, and Ser413. A Ser/ Ala substi-
tution of these sites did not apparently affect the associa-
tion of IFNaR2 and IRF9 (Figure S2). To confirm the view
that the acetyl-Lys399 or an acetyl-Lys399-phospho-
Ser400 motif is required for IRF9 binding, synthesized
peptides containing the flanking sequence of Lys399/
Ser400 were immobilized at three doses on nitrocellulose
membranes. Proteins prepared from control or Myc-IRF9
transfected 293T cells were incubated with these peptide
membranes then followed by anti-Myc probing. Only the
peptides bearing acetyl-Lys399 and acetyl-Lys399-phos-
pho-Ser400 interacted with IRF9 (Figure 3D). Consistently,
IFNa failed to induce the interaction between IFNaR2 and
IRF9 (Figure 3E) or IRF9 nuclear translocation (data not
shown) in CBP/ mouse embryonic fibroblast (MEF).
IFNa stimulation dependent IRF9 acetylation, nuclear
Figure 3. IFNaR2 ‘‘Acetyl-Lys399-Phospho-SerS400’’ Motif Is Specific for IRF9 Docking
(A) IFNaR2 recruits IRF9. Anti-Myc precipitates, prepared from 293T cells cotransfected with IFNaR2 and STAT2 or IRF9, were probed with anti-HA
(IFNaR2) or anti-Myc (IRF9 and STAT2).
(B) IFNaR2 ‘‘393–407’’ bears the IRF9 binding site. Myc-tagged forms of IFNaR2 C-terminal region as indicated were cotransfected with IRF9.
Anti-IRF9 precipitates were analyzed with anti-Myc or anti-IRF9 in western blot. In right panels, Myc-IFNaR2C constructs (i.e., 265–408 and 265–392)
were cotransfected with STAT2 in 293T cells. Anti-Myc precipitates were analyzed with anti-STAT2 or anti-Myc.
(C) Ace-K399 of IFNaR2 is for IRF9 docking. In 293T cells, IRF9 was transfected along with different forms of IFNaR2 as indicated. Anti-IRF9 precip-
itates were analyzed with anti-IFNaR2 or anti-IRF9.
(D) Peptides (CERRKSPLQDPF) with different modifications were printed on nitrocellulose membranes at indicated concentrations. In the left panel,
the membrane was stained with Poncau S. The two membranes in the right side were incubated with cell extracts prepared from 293T cells trans-
fected with empty vector or Myc-IRF9, followed by anti-Myc blotting.
(E) Anti-IFNaR2 precipitated IRF9 in control MEF but not in CBP/ MEF.
(F) IFNa-dependent IRF9 nuclear translocation (left), IRF9 acetylation (middle), and ISGF3 DNA-binding activity (right) were analyzed in U5A cells
transfected with empty vector, wild-type, or K399R mutated IFNaR2. Nuclear lysates were incubated with biotin-labeled ISRE oligonucleotide probe
for EMSA.translocation, and DNA-binding activity were restored
by expressing wild-type IFNaR2 but not by express-
ing IFNaR2-K399R mutant in IFNaR2 null U5A cells
(Figure 3F). These findings clearly demonstrate that CBP
is responsible for IFNaR2 acetylation. Moreover, while
IFNaR2 acetylation of Lys399 is sufficient for IRF9 recruit-
ment, phosphorylation of the neighboring serine site
(Ser400) further stabilizes the interaction between these
two proteins.The IRF9 IH2 Domain Is Responsible for the
Modular Interaction with Acetylated IFNaR2
We next analyzed the domain of IRF9 responsible for the
interaction with IFNaR2. The IRF9 C-terminal region can
be further divided into three domains according to sec-
ondary structural analysis (http://www.sbg.bio.ic.ac.uk/
3dpssm/index2.html): (1) the IRF homology1 domain
(IH1D) or transcriptional activation domain (340–393) con-
sists of a ‘‘ba’’ (or ‘‘baa’’ in other IRF members) secondaryCell 131, 93–105, October 5, 2007 ª2007 Elsevier Inc. 97
structure; (2) the IRF homology2 (IH2) domain (258–339)
consists of four b sheets sandwiched by two helices,
‘‘abbbba,’’ similar to the SH2 domain (Figure 4A); and (3)
the IRF homology3 (IH3) domain (200–257) consists of
four short b sheets ‘‘bbbb.’’ To identify which of these
C-terminal domains is required for IFNaR2 binding, we
prepared a series of Myc-tagged IRF9 domain deletion
mutants (Figure 4B) and cotransfected them with IFNaR2
in 293T cells. Coimmunoprecipitation results indicate that
the IH2 domain (258–393) bears the major interaction site
for IFNaR2, even though a weak interaction between the
N-terminal DBD (1–117) and IFNaR2 was observed
(Figure 4C). Deletion of the C-terminal IH1 domain (339–
393) disrupted IRF9 interaction with STAT2 (Figure 4D).
Given that the b5 and b6 motifs of the IH2 domain appear
as the swapped bB and bC motifs in the SH2 domain
(Figure 4A), we tested the significance of Arg292 of the
IH2 domain for IFNaR2 binding. IRF9 with Arg292/ Gln
substitution dramatically inhibited the IRF9 interaction
with IFNaR2 (Figure 4E). Although conserved aromatic
residues of the bromodomain often interact with the acet-
ylated lysine site through amide-p interaction, substitu-
tion of conserved aromatic residues with alanine (IRF9-
W300A, IRF9-F323F328A) did not affect IFNaR2 binding
(Figure 4E). Together, these findings support the notion
that the IH2 domain of IRF9 is responsible for the modular
interaction with IFNaR2, whereas the IH1 domain of IRF9
is for STAT2 recruitment.
IRF9 Acetylation on Helix-a3 Lysine Is Required
for IRF9 Dimerization and DNA Binding
Like IFNaR2, IRF9 acetylation was inducible upon IFNa
treatment in HeLa cells but not in the HeLa cells with
CBP downregulated (Figure 5A). CBP was also the most
effective one among the acetyltransferases tested for
catalyzing IRF9 acetylation in 293T cells (Figure 5B).
For some IRF family members, the acetylated lysine sites
have been exclusively identified within the N-terminal
DBD (Figure S2B). To identify the acetylated lysine sites
of IRF9, we mutated all conserved lysine sites within the
IRF9 N-terminal domain. Surprisingly, in IRF9 null U2A
cells, K/ R mutagenic analysis of the IRF9 acetylation
pattern did not provide any information regarding which
lysine is acetylated by CBP because none of the IRF9-
KR mutants appeared impaired by acetylation as
accessed by blotting analysis (Figure 5C). Several IRF9-
KR mutants became more sensitive to acetylation by
CBP (Figure 5C), suggesting that IRF9 can be hypo- or
hyperacetylated. When mass spectrometry was em-
ployed, eight acetylated peptides were recovered from
IRF9 (Figure 5D). All acetylated lysine sites that reside
within the N-terminal domain and are highly conserved
in IRF9 through different species. When aligned with other
IRF family members, however, Lys81, the helix-a3 lysine,
is the only one conserved among all members (Fig-
ure S2B).
In IRF2 and IRF7, the helix-a3 lysine (Lys78 and Lys92,
respectively) is the major acetylation site and is thought98 Cell 131, 93–105, October 5, 2007 ª2007 Elsevier Inc.to regulate DNA-binding activity (Caillaud et al., 2002;
Masumi et al., 2003). To determine an effect of IRF9 acet-
ylation on DNA binding, we cotransfected either wild-type
IRF9 or IRF9-KR mutants with CBP into U2A cells and
performed EMSA using whole-cell extracts and a 32P-
labled ISRE oligonucleotide from the ISG15 gene
promoter. IRF9-K81R virtually abolished its DNA-binding
activity (Figure 5E). Three-dimensional and protein-inter-
action analysis revealed that the N-terminal DBD and the
C-terminal transcriptional activation domain in a latent
IRF molecule are either in contact or in close proximity
and that dimerization is required for IRF to bind to DNA
(Brass et al., 1996; Lin et al., 1999; Qin et al., 2003). It
was tempting to speculate that IRF9 acetylation on
Lys81 was needed for IRF9 to undergo dimerization within
two different domains. Coimmunoprecipitation results
revealed that IRF-DBD but not IRF9-DBD with K81R
substitution associated with IRF9 either full-length or the
C-terminal 118–393 fragment (Figure 5F, right panel).
Thus, helix-a3 lysine acetylation plays a pivotal role
in IRF dimerization, requiring an interaction between the
N-terminal and C-terminal domains.
STAT2 Acetylation on Lys390 Regulates
STAT2:STAT1 Interaction
STAT2 is another important component of ISGF3 com-
plex, and its acetylation was similar to IFNaR2 and IRF9
acetylation in many respects: CBP downregulation largely
abolished STAT2 acetylation induction by IFNa (Fig-
ure 6A), and CBP was more potent than transferases
tested in catalyzing STAT2 acetylation (Figure 6B). Mass
spectrometry identified nine acetylated lysine sites within
STAT2 proteins prepared from 293T cells cotransfected
with STAT2 and CBP or p300. While four acetyl-lysine
sites reside within the b-barrel DBD (Figure 6C), others
reside within the coiled coil and the SH2 domains (Table
S2). Interestingly, and differing from IRF, acetylated lysine
sites are poorly conserved among STAT members
(Figure 6D).
To investigate the effect of STAT2 acetylation on ISGF3
complex formation, we started with the N-terminal coiled-
coil domain. In agreement with previous publications
(Horvath et al., 1996; Martinez-Moczygemba et al., 1997),
this domain of STAT2 (1–314) and IRF9 coprecipitated
(Figure S3A). However, acetylation within the coiled-
coil domain did not seem to be involved in this regulatory
interaction since a K/ R substitution of the four acety-
lated sites within this domain did not alter the STAT2:
IRF9 interaction (Figures S3B and S3C).
We then examined STAT2 acetylation within the b-bar-
rel DBD. A direct interaction between the STAT2-DBD
(315–485) and STAT1 was detected (Figure 6E) (Li et al.,
1997). While STAT2 with a K384R or K419R substitution
moderately weakened the STAT2 and STAT1 interactions,
STAT2-K390R and to a lesser extent STAT2-K415R inter-
acted more strongly with STAT1 (Figure 6F, left panel).
Among these acetylated sites within the b-barrel DBD,
Lys390 is least conserved. Lys390 from STAT2 of human
Figure 4. The IH2 Domain of IRF9 Mediates Its Modular Interaction with IFNaR2
(A) The IH2 domain of IRF family members is aligned with the SH2 domain of Src. Yellow shading indicates b sheet and the blue shading indicates
a helix.
(B) Schematic illustration of domain deletion constructs of IRF9 tagged with 6 3 Myc at the N terminus: DNA-binding domain (DBD), linker domain
(LD), IRF homology 3 domain (IH3D), IRF homology 2 domain (IH2D), and IRF homology 1 domain (IH1D).
(C) IH2D (257–338) of IRF9 is responsible for IFNaR2 binding. Anti-IFNaR2 precipitates, prepared from these 293T cells cotransfected with IFNaR2
and IRF9 mutants, were analyzed with anti-Myc (IRF9) or anti-IFNaR2.
(D) IH1D (339–393) of IRF9 interacts with STAT2. Anti-HA precipitates, prepared from 293T cells cotransfected with HA-STAT2 and Myc-IRF9 of
different domains, were probed with anti-HA and anti-Myc simultaneously.
(E) b6-Arg (R292) of IRF9 is critical for IFNaR2 binding. Anti-IFNaR2 precipitates, prepared from the 293T cells transfected with IFNaR2 and Myc-IRF9
(wild-type or mutant), were probed with Myc or IFNaR2 Ab.origin was replaced by glutamate in STAT2 of murine
origin (Figure S3D). STAT2 with a K390E substitution
restored the pattern of the interaction between STAT2
and STAT1 observed with wild-type STAT2 (Figure 6G).
STAT1 also bears a negatively charged residue (Glu394)
at the same position (Figure 6D). However, STAT1 with
both E393 and E394 changed to alanine showed no effect
on the elevated interaction between STAT1 and STAT2-
K390R (Figure 6G). In contrast, STAT2 DBD acetylation
seemed to be irrelevant to STAT2’s interaction with IRF9
(Figure 6F, right panel) or STAT3, which can also form het-
erodimer with STAT2 (Figure S3E). These findings imply
that endogenous STAT1 and STAT2 in human cells might
form a heterodimer prior to cytokine treatment. Indeed, we
repeatedly detected a stable STAT1:STAT2 interaction,
which was slightly diminished following IFNa treatment
in HeLa cells (Figure 6H). To estimate STAT2-K390R mu-
tant on ISGF3 complex formation, Myc-tagged forms of
IRF9 and STAT1 were cotransfected with Myc-taggedSTAT2 wild-type or K390R mutant in STAT2 null U6A cells.
STAT1 precipitates prepared from these transfectants
were blotted with either STAT2 antibody or IRF9 antibody,
and their blotting signal intensities were plotted in arbitrary
units (Figure 6I). Even though K390R mutated STAT2
became avidly bound to STAT1 (Figure 6I, left), lesser
amount of IRF9 was recovered from STAT1 precipitants
obtained from U6A cells expressing STAT2-K390R mutant
(Figure 6I, right). Although STAT1 was also acetylated
(Kramer et al., 2006), an effect of STAT1 acetylation (Fig-
ures S4A and S4B) on the ISGF3 complex formation was
not appreciated in this work. Recently, Mertens et al.
suggested that activated STAT1 form homodimers via
their SH2-domain interaction, whereas quiescent STAT1
form homodimers via their DBD interaction (Mertens
et al., 2006). Our results clearly indicate that STAT2:STAT1
interaction was mainly regulated by STAT2 acetylation on
Lys390, which dissociates DBD of STAT2 from STAT1,
a step required for the active ISGF3 complex formation.Cell 131, 93–105, October 5, 2007 ª2007 Elsevier Inc. 99
Figure 5. IRF9 Acetylation on Lys81 Acetylation Is Required for IRF9 Dimerization
(A) In HeLa cells, CBP siRNA transfection abolished IRF9 acetylation.
(B) IRF9 acetylation was analyzed in 293T cells by cotransfecting IRF9 with different HAT factors.
(C) Site-directed K/ R mutagenic analysis of IRF9 acetylation by CBP. IRF9-KR mutants were cotransfected with CBP in U2A cells and analyzed
with acetylation blotting.
(D) MS/MS spectra of acetylated peptides recovered from IRF9 prepared from 293T transfectants. Lysine residues with 42-dalton mass changes are
marked as K*.
(E) K81R mutation abolishes IRF9 DNA-binding activity. Nuclear lysates, prepared from U2A cells transfected with different forms of IRF9 and treated
with IFNa for 30 min, were incubated with 32P-labeled ISRE oligonucleotide as the probe for EMSA.
(F) K81 acetylation is required for IRF9 dimerization between the N-terminal 1-118 and the C-terminal 340-393 regions. In the left panel, Myc-DBD (1-
118) of IRF9 was cotransfected with 118-393, 118-339, or 1-393 (FL) of IRF9 in 293T cells. Anti-IRF9 (C-terminal region) precipitates were analyzed
with anti-Myc or anti-IRF9. Anti-IRF9 precipitates, prepared from 293T cells cotransfected with the C-terminal fragment 118-393 of IRF9 and Myc-
tagged DBD of different forms, were analyzed with anti-Myc or anti-IRF9 (right panel).A CBP-Mediated Acetylation Cascade Plays
a Critical Role in ISGF3 Antiviral Activity
To investigate the significance of the CBP-mediated acet-
ylation cascade on antiviral gene regulation by the ISGF3
complex, we manipulated CBP protein levels in cells. To
do this, we first tested CBP overexpression on ISG54
promoter activation in 293T cells. Overexpression of
CBP boosted the ISGF3 complex activity by a factor of
5-fold (Figure 7A). In contrast, introduction of the siRNA
targeting CBP but not a control siRNA into the cells mark-
edly inhibited ISGF3 transcriptional activity (Figure S5A).100 Cell 131, 93–105, October 5, 2007 ª2007 Elsevier Inc.Importantly, the effect of STAT1 on IRF9 and STAT2
cotransfection-dependent transcriptional activity could be
converted from weakly negative into largely positive by
also cotransfecting CBP (comparing the last two groups
in Figure 7A). These findings support the notion that the
conformational change of the STAT1:STAT2 heterodimer
as regulated by STAT2 acetylation on the Lys390 site is
critical for an active ISGF3 complex formation.
IFNaR2, IRF9, and STAT2 null cell lines developed by
George Stark and coworkers were then used to examine
acetylation of these factors on transcriptional activation.
Figure 6. STAT2 Lys390 Acetylation Controls Steady-State STAT2:STAT1 Interaction
(A) In HeLa cells, CBP siRNA transfection abolished STAT2 acetylation.
(B) STAT2 acetylation was analyzed in 293T cells by cotransfecting STAT2 with different HAT factors.
(C) MS/MS spectra of the three acetylated peptides of STAT2 b-barrel DBD. Lysine residues with 42-dalton mass changes are marked as K*.
(D) STAT2 DBD, which carries four acetylated-lysine sites, is aligned with other STAT family members.
(E) STAT2 DBD interacts with STAT1. Anti-STAT1 precipitates, prepared from 293T cells cotransfected with STAT1 and STAT2 N-terminal domain or
DBD, were analyzed in western blot with anti-Myc.
(F) STAT2-K390R became prominent in heterodimerization with STAT1. As indicated, STAT2-KR mutants were cotransfected with STAT1 (left panel)
or IRF9 (right panel). Anti-STAT1 precipitates (left panel) or anti-IRF9 precipitates (right panel) were then analyzed for STAT2 binding in western blot.
(G) Anti-STAT1 precipitates, prepared from 293T cells cotransfected with STAT1-WT or STAT1-E93E394A and STAT2 of different forms, were
analyzed with anti-STAT2 in western blot.
(H) STAT2 and STAT1 heterdimerization prior and subsequent to IFNa treatment in HeLa cells.
(I) STAT2-K390R substitution has reduced activity in ISGF3 complex formation. In U6A cells, the Myc-tagged constructs of STAT1, IRF9, and STAT2
(WT or K390R) were cotransfected followed by IFNa treatment for 30 min. Anti-STAT1 precipiates were subjected to anti-Myc western blot. The signal
intensities of the bands corresponding to STAT2 (left panel) and IRF9 (right panel) were obtained by phosphoimage densitometry analysis.In U5A cells, the introduction of wild-type IFNaR2 restored
the cellular response to IFNa in an ISG45 promoter-lucifer-
ase reporter assay (Figure 7B, left). With the same condi-
tions, IRF9 docking site mutated IFNaR2, CBP binding site
mutated IFNaR2, or wild-type IFNaR2 plus HDAC6 allabolished the cellular response to IFNa (Figure 7B, left).
When all KR mutants of IRF9 and STAT2 were tested,
IRF9-K81R in U2A cells and STAT2-K390R in U6A cells
failed to respond to IFNa in ISGF3 promoter reporter
activation (Figure 7B; middle, right). We then preparedCell 131, 93–105, October 5, 2007 ª2007 Elsevier Inc. 101
Figure 7. IFNaR-ISGF3 Pathway Acetylation Transcriptionally Regulates Antiviral Activity
(A) CBP-dependent activation of ISGF3 complex in activating ISG54 promoter-luciferase reporter in 293T cells. Results for this and all subsequent
experiments are represented as fold induction over control (mean ± SD of three different experiments).
(B) IFNaR2, IRF9, and STAT2 of different mutation forms as indicated were tested for activation of ISG54 promoter-luciferase reporter in U5A, U6A,
and U2A cells respectively. In U5A cells, HDAC6 and IFNaR2 cotransfection on ISG54 promoter-luciferase reporter activation was included.
(C) U5A, U2A, and U6A cells transfected with indicated constructs were treated with or without IFNa for 1 hr. Genomic DNA elutes prepared from
anti-ISGF3 precipitates were analyzed by ChIP assays with 616 promoter (616 Pm) primers. Genomic DNA without immunoprecipitation was
used as input.102 Cell 131, 93–105, October 5, 2007 ª2007 Elsevier Inc.
genomic DNA from these U5A, U2A, and U6A cells treated
with IFNa for chromatin immunoprecipitation (ChIP)
analysis. PCR products from ChIP experiments, corre-
sponding to the region (453 to 91) of the 616 gene
promoter, which, centrally spanned with two ISRE motifs,
were examined. The correct PCR products were enriched
in response to IFNa treatment in the IRF9, and STAT2 were
precipitates obtained only from those cells expressing
wild-type IFNaR2, IRF9, or STAT2 but not from those cells
transfected with empty vector or critical lysine mutants of
IFNaR2, IRF9, or STAT2 (Figure 7C).
CBP-mediated acetylation of IFNa signaling factors
were further analyzed in antiviral gene regulation. Since
ISGF3 components failed to respond to IFNa for nuclear
translocation in CBP/ MEF (Figure 7D), the induction
of antiviral genes 927, 616, ISG15, and ISG54 by
IFNa was largely inhibited (Figure 7E). It further supports
a critical role of CBP as a cytoplasmic acetyltransferase
for IFNa signaling. In human lung fibrosarcoma 2fTGH
cells, the parental line of U5A, U2A, and U6A cells, the
above antiviral genes were all induced by IFNa in a
time-dependent manner (Figure S5B). In U5A, introduc-
tion of wild-type but not K399R substituted IFNaR2
restored IFNa- dependent antiviral gene induction
(Figure 7F, left) and cell antiviral activity (Figure 7G, left).
Cotransfection of HDAC6 with wild-type IFNaR2 abol-
ished this IFNa-dependent cell antiviral activity in U5A
cells (Figure 7G, left). Similarly, in U2A or U6A cells, intro-
duction of wild-type but not specific K81R substituted
IRF9 or K390R substituted STAT2 restored IFNa-depen-
dent antiviral gene induction (Figure 7F; middle, right)
and cell antiviral activity (Figure 7G; middle, right). Collec-
tively, these results strongly support our conclusion that
CBP-mediated IFNaR2 acetylation on Lys399, IRF9 acet-
ylation on Lys81, and STAT2 acetylation on Lys390 func-
tion together in response to IFNa during antiviral signal
transduction.
DISCUSSION
Tyrosine phosphorylation has long been considered to
play the central role in signal transduction for many cyto-
kines in mammalian cells. Here, we provide evidence
that a CBP-mediated acetylation cascade together with
serine phosphorylation plays a critical role in IFNa-initi-
ated intracellular signaling (Figure 7H). Nuclear export of
CBP upon UV stimulation has been previously noted
(Cohen et al., 2004). A serine phosphorylation-dependent
mechanism may play a role in CBP nuclear exportation,
similar to HDAC nuclear export (McKinsey et al., 2000).CBP/p300 can bind with many transcription factors at
phosphoserine sites flanked with proline residues or
negatively charged residues. In IFNaR2, phosphorylation
of Ser364 and Ser384 sites may be further coordinated
with the already negatively charged local environment for
CBP recruitment. Given that Ser364, Ser384, and Ser400
sites are flanked with charged residues and proline,
a kinesin spindle protein (KSP) type kinase may be re-
sponsible for their phosphorylation.
In histone H3, the ‘‘RK9S’’ or ‘‘RK27S’’ motif where
lysine can be either methylated or acetylated serves as
the docking site for heterochromatin protein 1 (HP1) or
polycomb (Pc) (Fischle et al., 2003, 2005; Hirota et al.,
2005). According to the ‘‘methyl/phos switch’’ model,
serine phosphorylation of the ‘‘RKS’’ motif that engages
an HP1 or Pc module could lead to consecutive loss
of binding. In the IFNaR2 cytoplasmic region, acetyl-
Lys399 provides IRF9 with a docking site, whereas phos-
phorylation of the adjacent Ser400 seems to consolidate
this interaction. In the SH2, WW, and MH2 domains, con-
served arginine and aromatic residues often play critical
roles in their modular interactions (Wu et al., 2001). In
the IH2 domain, although those conserved aromatic resi-
dues may still provide an amide-p contact, b6-Arg (R292)
seems to play a more important role in modulating inter-
action with the acetyl lysine presumably by providing
a noncovalent contact.
Both IRF9 and STAT2 of an active ISGF3 complex are
highly acetylated within their DBD. For transcription
factors such as p53, acetylation within DBD mediates
regulatory interaction with other cofactors without af-
fecting its DNA-binding activity (Sykes et al., 2006;
Tang et al., 2006). For IRF family members, acetylation
on the family conserved helix-a3 lysine within DBD
presumably results in the conformational change (i.e.,
dimerization) required for DNA binding. In the case of
IRF3, its dimerization requires serine phosphorylation
within the ‘‘serine rich loop-helix a5’’ C tail to unlock
the C- and N- terminal domains (Takahasi et al.,
2003). Lacking the C-terminal ‘‘serine rich loop-helix
a5’’ tail, IRF9 dimerizes for DNA binding via Lys81 acet-
ylation, a reminiscence of STAT3 acetylation on Lys685
for dimerization. In STAT2, Lys390 within DBD is poorly
conserved. Although it is unclear whether Lys390 is an
evolutionary mistake requiring acetylation for correction
or it has a function evolved specially for human cells,
STAT2 acetylation on this site may warrant a more flex-
ible interaction between STAT2 and STAT1, allowing
STAT1 to interact with IRF9 and DNA within the ISGF3
complex.(D) IRF9 and STAT2 nuclear translocation in control or CBP/ MEF treated with or without IFNa (30 min) were analyzed in western blot.
(E) IFNa(12 hr)-induced mRNA expression of indicated antiviral genes was analyzed by RT-PCR in control and CBP/ MEFs.
(F) IFNa-induced mRNA expression of four antiviral genes was analyzed by RT-PCR in U5A, U2A, and U6A cells transfected with different forms of
IFNaR2, IRF9, and STAT2 as indicated.
(G) IFNa antiviral activity was analyzed in U5A, U2A, and U6A cells transfected with IFNaR2, IRF9, and STAT2 of different forms, as indicated respec-
tively. All the cells were treated with IFNa for 6 hr followed by viral infection for another 24 hr. Results are represented as fold induction over untreated.
(H) A model for CBP-mediated acetylation cascade in IFNa signal transduction is illustrated.Cell 131, 93–105, October 5, 2007 ª2007 Elsevier Inc. 103
CBP/p300 play a critical role in type I interferon antiviral
activity. Adenovirus E1A inhibits IFNa response in the
ISGF3 complex formation, STAT2 transactivity, and antivi-
ral gene expression, allowing viral replication presumably
by targeting CBP/p300 (Kalvakolanu et al., 1991; Bhatta-
charya et al., 1996). In this respect, the profound impair-
ment in IFNa-dependent viral-suppressive activities
observed in CBP null cells is in agreement with the fre-
quent loss of CBP/p300 activity in viral infected cells
where the IFNa pathway is impaired. Although CBP is
a transcriptional cofactor, which can affect ISGF3 tran-
scriptional activity in nuclei, IFNaR2 failed to recruit
IRF9, and both IRF9 and STAT2 failed to undergo nuclear
translocation in response to IFNa treatment in CBP/
MEF. Therefore, CBP can function as a primary cytoplas-
mic acetyltransferase for IFNa receptor signaling here.
Our findings provide important molecular insights into
the acetylation cascade in mediating cytokine receptor
signal transduction.
EXPERIMENTAL PROCEDURES
Cell Culture and Expression Constructs
All the cell lines were cultured in Dulbecco’s modified Eagle’s medium
(Invitrogen, Carlsbad, CA) with 10% fetal bovine serum. STAT2,
STAT1, IRF9, and IFNaR2 mutagenesis was performed using Quick-
Change XL site-directed mutagenesis kit (Stratagene, La Jolla, CA)
or two-step PCR. IFNaR2 C-terminal tail truncation mutants, IRF9
domain deletion mutants, and STAT2 domain constructs were
constructed by performing PCR amplification. PCR products were
then subcloned into a pCDNA3.1 vector with a 6 3 Myc tag at the N
terminus. All cDNA constructs used in this project were verified by
sequencing. All transfections were performed with Lipofectamine
2000 (Invitrogen) in accordance with the manufacturer’s instructions.
LC-MS/MS Mass Spectrometry Analysis of Proteins
with Posttranslational Modifications
In 293T cells, IFNaR2, IFNaR1, IRF9, or STAT2 was cotransfected with
CBP followed by IFNa treatment for 30 min or left no treatment. Immu-
noprecipitated IFNaR2, IFNaR1, IRF9, or STAT2 proteins from the
transfectants were resolved by 10% SDS-PAGE and visualized using
Coomassie blue stain. The bands of the above proteins (1–2 mg)
were excised and subjected to mass spectrometry analysis performed
by Taplin Biological Mass Spectrometry Facility (Boston, MA) as
described previously (Yuan et al., 2005).
Immunostaining, Immunoprecipitation, Western Blot,
Peptide Slot Blot, ChIP, DNA Binding, and Luciferase
Reporter Assays
Cell (HeLa or 2fTGH) immunostaining was performed as described
(Yuan et al., 2005). CBP and DAPI probing was preceded by in situ
cell fractionation. Confocal sections were obtained with a LeicaTCS
SP2 AOBS confocal laser microscope by sequential scanning. For
immunoprecipitation and western blot, cells were lysed in RIPA buffer.
Approximately 4 mg of protein was incubated with 4 mg of monoclonal
anti-IFNaR2, anti-Myc, anti-IRF9, or polyclonal anti-STAT2 for 6 hr or
overnight at 4C. Immunocomplexes were collected on protein G-aga-
rose beads separated by 8%–10% SDS-PAGE and electroblotted to
nitrocellulose membrane. Proteins were detected after incubation
with specific antibodies described about or antiacetylated lysine and
followed by Alex680- or IR700-conjugated secondary antibody for
LICOR analysis. For peptide dot blot assay, three dilutions of the
four peptides with the indicated modifications were spotted onto a104 Cell 131, 93–105, October 5, 2007 ª2007 Elsevier Inc.nitrocellulose membrane. Such prepared membranes were incubated
with whole cell extracts followed by three washes and anti-Myc immu-
noblotting analysis. The 4 peptides of 12 amino acid residues were
synthesized as CERRKSPLQDPF, CERRaceKSPLQDPF, CERRK-
phoSPLQDPF, and CERRaceKphoSPLQDPF, purified with HPLC up
to 98% purity. ChIP assay was carried out according to the manufac-
turer’s protocol (Upstate). In brief, cells were left untreated or treated
with IFNa (1000 U/ml) for 1 hr. Histone and DNA were crosslinked by
adding 1% formaldehyde, and the cell lysates were made with SDS
lysis buffer for sonication. Following immunoprecipitation of the diluted
lysates with anti-ISGF3 (anti-IRF9/anti-STAT2), the eluates were
reversed crosslinks and subjected to PCR (21 cycle) with the primers
for 616 promoter (50-GGTGAAAGGCCTGTGTGCC-30 and 50-CAGC
GAGTAAACGGTTCTCCG-30). For the electrophoretic mobility shift
assay (EMSA), nuclear extracts were prepared from U2A or U5A trans-
fectants and incubated for 20 min at room temperature with
[a32P]dCTP- or biotin-labeled double-stranded oligonucleotide probe
representing the ISRE site from the ISG15 gene 50-GGGAAAGG
GAAACCGAAACTGAA (114/92). Antibodies were incubated with
nuclear extract 60 min prior to the addition of probe for supershift.
For luciferase reporter assay, cells were transfected with ISG54-pro-
moter luciferase reporter and cDNAs for test by the lipofectamine
method in triplicates. Cellular extracts were collected 24 hr after trans-
fection for luminescent luciferase analysis measured with commercial
reagents (Promega, Madison, WI).
CBP siRNA Knockdown, RT-PCR, and Antiviral
Activity Assays
Cells (13 106) in 6-well dishes were transiently transfected with 15 nM
20–25 nt siRNA specific for CBP or control 20–25 nt siRNA (Santa Cruz
Biotechnology, Santa Cruz, CA) by the lipofectamine method. Whole
cell extracts were prepared 48 hr after transfection for immunoprecip-
itation and/or western blot analysis as described in the text. To analyze
antiviral genes, 2fTGH, U2A, U5A, and U6A cells in 6-well dishes were
treated with or without 1000 IU/ml of IFNa for 12 hr and total RNA was
isolated using Trizol reagent (Invitrogen) according to the manufac-
turer’s protocol. One microgram of total RNA was reversely tran-
scribed into cDNA using the Clontech RT kit and random primer (Prom-
ega). RT-PCR primers for antiviral genes were described previously
(Figure S5B). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
with forward 50- TTCCTCTCCTCGCTCCAGTC -30 and reverse 50- AGT
GCGAGCCCTGACTTCCT -30 was used as a control. PCR was per-
formed in a final volume of 25 ml containing 0.4 mM of each primer
and 1 ml of template cDNA. IFNa antiviral responses were measured
by vesicular stomatitis virus (VSV)-pseudotyped HIV-1 infection assay
(Sancho et al., 2004). In brief, pNL4-3.Luc.R-E- (pNL4-3 nef gene in-
serted with the firefly luciferase gene) and the pcDNA3-VSV plasmid
encoding the vesicular stomatitis virus G protein were cotransfected
in 293T cells using the lipofectamine 2000. The cell-free supernatants
containing the virus stocks were collected 48 hr after transfection.
U5A, U2A, or U6A transfectants in 12-well dishes were pretreated
with or without IFNa for 12 hr followed by inoculating with the viruses
stocks and 10 mg/ml polybrene for an additional 24 hr. The cells were
washed with phosphate-buffered saline and lysed in 100 ml of passive
lysis buffer for luciferase activity analysis by adding 100 ml substrates.
Supplemental Data
Supplemental Data include five figures and two tables and can be
found with this article online at http://www.cell.com/cgi/content/full/
131/1/93/DC1/.
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